The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 01, 2020
Filed:
May. 13, 2019
Applicant:
Theravance Biopharma R&d Ip, Llc, South San Francisco, CA (US);
Inventors:
Roland Gendron, El Verano, CA (US);
Adam D. Hughes, Half Moon Bay, CA (US);
Assignee:
Theravance Biopharma R&D IP, LLC, South San Francisco, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 498/08 (2006.01); C07D 231/18 (2006.01); C07D 233/26 (2006.01); C07D 237/24 (2006.01); C07D 239/34 (2006.01); C07D 241/24 (2006.01); C07D 249/10 (2006.01); C07D 249/18 (2006.01); C07D 257/04 (2006.01); C07D 261/20 (2006.01); C07D 263/34 (2006.01); C07D 271/06 (2006.01); C07D 277/56 (2006.01); C07D 307/68 (2006.01); C07D 333/70 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 403/04 (2006.01); C07D 405/12 (2006.01); C07D 409/06 (2006.01); C07D 471/04 (2006.01); C07D 498/04 (2006.01); C07D 261/18 (2006.01); C07D 207/34 (2006.01); C07D 239/36 (2006.01); C07D 413/06 (2006.01); A61K 31/422 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 413/12 (2006.01); C07D 213/79 (2006.01); C07D 237/04 (2006.01); C07D 249/08 (2006.01); C07D 249/12 (2006.01); C07D 261/12 (2006.01); C07D 263/56 (2006.01); C07D 277/46 (2006.01); C07D 333/40 (2006.01); C07D 213/81 (2006.01); C07D 231/14 (2006.01); C07D 233/90 (2006.01); C07D 249/04 (2006.01); C07D 403/06 (2006.01); A61K 31/42 (2006.01); C07D 413/04 (2006.01); C07D 213/80 (2006.01);
U.S. Cl.
CPC ...
C07D 498/08 (2013.01); A61K 31/42 (2013.01); A61K 31/422 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 207/34 (2013.01); C07D 213/79 (2013.01); C07D 213/80 (2013.01); C07D 213/81 (2013.01); C07D 231/14 (2013.01); C07D 233/26 (2013.01); C07D 233/90 (2013.01); C07D 237/04 (2013.01); C07D 237/24 (2013.01); C07D 239/34 (2013.01); C07D 239/36 (2013.01); C07D 241/24 (2013.01); C07D 249/04 (2013.01); C07D 249/08 (2013.01); C07D 249/10 (2013.01); C07D 249/12 (2013.01); C07D 249/18 (2013.01); C07D 257/04 (2013.01); C07D 261/12 (2013.01); C07D 261/18 (2013.01); C07D 261/20 (2013.01); C07D 263/34 (2013.01); C07D 263/56 (2013.01); C07D 271/06 (2013.01); C07D 277/46 (2013.01); C07D 277/56 (2013.01); C07D 307/68 (2013.01); C07D 333/40 (2013.01); C07D 333/70 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 405/12 (2013.01); C07D 409/06 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01);
Abstract
In one aspect, the invention relates to compounds having the formula: where R-R, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.